A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma

Phase 2

Completed

• Conditions: Sarcoma, Kaposi; HIV Infections

• Registration Number: NCT00002212
• Lead Sponsor: Ligand Pharmaceuticals

Brief Summary

The purpose of this study is to see if it is safe and effective to give Targretin capsules to patients with AIDS-related Kaposi's sarcoma (KS).

Detailed Description

This is a multicenter, open-label study to evaluate the safety and efficacy of Targretin capsules in patients with AIDS-related KS. NOTE: The daily dose may be reduced as necessary for toxicity management.

Study Timeline

• Status Verified: 1999-04
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (3)

Tulane Univ School of Medicine; 🇺🇸 New Orleans, Louisiana, United States

Desert Univ School of Medicine; 🇺🇸 Palm Springs, California, United States

Milton S Hershey Med Ctr; 🇺🇸 Hershey, Pennsylvania, United States